Pay in 4 interest-free payments of $5.00 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
a 2025 literature review identified limited clinical evidence, including a retrospective study of 12 patients with knee pain and a Phase I trial in healthy volunteers whose results were not submitted
Jan 7 2022;12(2)doi:10.3390/ani12020141
This compound represents a significant advancement in neuropharmacology as it was specifically engineered to overcome the limitations of its parent moleculeprimarily poor blood-brain barrier penetration and rapid metabolic degradation
advanced protocols extend to 6 months with periodic lab monitoring Research status: The primary human evidence for CJC-1295 comes from a 2006 randomized, placebo-controlled phase II trial in healthy adults (Teichman et al., J Clin Endocrinol Metab) showing dose-dependent GH increases of 2- to 10-fold lasting 6+ days and IGF-1 elevations lasting up to 28 days after multiple doses with no serious adverse events
